ARBs	inhibit	angiotensin II
ARBs	block	AT1 receptor
AT1 receptor	mediates	vasoconstriction
vasoconstriction	increases	blood pressure
blood pressure	measured by	systolic pressure
blood pressure	measured by	diastolic pressure
ARBs	treat	hypertension
hypertension	risk factor for	stroke
hypertension	risk factor for	myocardial infarction
ARBs	reduce	proteinuria
proteinuria	marker of	kidney disease
kidney disease	classified by	eGFR
eGFR	calculated from	serum creatinine
serum creatinine	measured by	blood test
ARBs	used in	heart failure
heart failure	classified by	NYHA class
NYHA class	predicts	mortality
mortality	predicted by	LVEF
LVEF	measured by	echocardiogram
echocardiogram	performed by	cardiologist
ARBs	prescribed with	ACE inhibitors
ACE inhibitors	contraindicated in	pregnancy
pregnancy	monitored by	obstetrician
ARBs	side effect	hyperkalemia
hyperkalemia	monitored by	potassium level
potassium level	measured by	blood test
ARBs	side effect	cough
cough	differential diagnosis	ACE inhibitor cough
ARBs	side effect	dizziness
dizziness	leads to	fall risk
fall risk	increases	readmission
readmission	predicted by	frailty score
frailty score	calculated from	gait speed
gait speed	measured by	4‑meter walk
ARBs	drug class	antihypertensive
antihypertensive	subclass	vasodilator
vasodilator	mechanism	nitric oxide
nitric oxide	produced by	endothelial cells
endothelial cells	dysfunction in	diabetes
diabetes	risk factor for	ARBs efficacy
ARBs	efficacy	measured by	BP reduction
BP reduction	correlated with	cardiovascular events
cardiovascular events	include	arrhythmia
arrhythmia	detected by	ECG
ECG	performed by	electrophysiologist
ARBs	dosage	titrated by	clinician
clinician	specialty	internal medicine
internal medicine	consults	pharmacy
pharmacy	monitors	drug interactions
drug interactions	include	potassium‑sparing diuretic
potassium‑sparing diuretic	increases	potassium level
potassium level	high risk for	arrhythmia
arrhythmia	treated with	beta‑blocker
beta‑blocker	contraindicated in	asthma
asthma	monitored by	pulmonologist
pulmonologist	uses	spirometry
spirometry	measures	FEV1
FEV1	predicts	exacerbation risk
exacerbation risk	leads to	hospitalization
hospitalization	predicted by	comorbidity index
comorbidity index	includes	COPD
COPD	risk factor for	ARBs side effect
ARBs	contraindicated in	severe renal impairment
renal impairment	staged by	CKD stage
CKD stage	staged by	eGFR
eGFR	declines with	age
age	risk factor for	polypharmacy
polypharmacy	increases	adverse drug reaction
adverse drug reaction	monitored by	pharmacist
pharmacist	reviews	medication list
medication list	includes	ARBs
ARBs	brand name	losartan
losartan	metabolized by	CYP2C9
CYP2C9	polymorphism	affects drug level
drug level	measured by	plasma concentration
plasma concentration	informs	dose adjustment
dose adjustment	guided by	therapeutic drug monitoring
therapeutic drug monitoring	performed by	clinical pharmacology
clinical pharmacology	collaborates with	cardiology
cardiology	monitors	heart rate
heart rate	measured by	Holter monitor
Holter monitor	records	arrhythmia episodes
arrhythmia episodes	predict	sudden cardiac death
sudden cardiac death	prevented by	ICD
ICD	implanted by	electrophysiology
electrophysiology	uses	cardiac imaging
cardiac imaging	includes	cardiac MRI
cardiac MRI	assesses	myocardial fibrosis
myocardial fibrosis	predicts	heart failure progression
heart failure progression	leads to	increased mortality
mortality	reduced by	ARBs therapy
ARBs therapy	adherence measured by	pharmacy refill
pharmacy refill	indicates	medication possession ratio
medication possession ratio	predicts	adherence
adherence	influences	blood pressure control
blood pressure control	reduces	stroke risk
stroke risk	mitigated by	antiplatelet therapy
antiplatelet therapy	contraindicated with	anticoagulant
anticoagulant	monitored by	INR
INR	maintained within	therapeutic range
